Search
BMS-986104
go.drugbank.com/drugs/DB15214Investigationalof BMS-986104 in Healthy Male Subjects). … BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
Caroxazone
go.drugbank.com/drugs/DB09254ApprovedWithdrawnHowever, it presents a five-fold preference for the MAO-B subtype. … Caroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeMorphine glucuronide
go.drugbank.com/drugs/DB06409InvestigationalCategories: Heterocyclic Compounds with 4 or More RingsBucetin
go.drugbank.com/drugs/DB13278ApprovedWithdrawnBucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]
DFV890
go.drugbank.com/drugs/DB16461InvestigationalDFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic
Categories: Experimental Unapproved Treatments for COVID-19Normethadone
go.drugbank.com/drugs/DB11609ApprovedIllicitNormethadone is used as an opioid antitussive in combination with [DB11610]. It is marketed in Canada by Valeant under the tradename Cophylac.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: Isomethadone IFlucloxacillin
go.drugbank.com/drugs/DB00301ApprovedInvestigationalWithdrawnAntibiotic analog of cloxacillin.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseLonidamine
go.drugbank.com/drugs/DB06266InvestigationalLonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK). … In such way LND could impair energy-requiring processes, as recovery from potentially lethal damage, induced by radiation treatment and by some cytotoxic drugs.
Cositecan
go.drugbank.com/drugs/DB05806InvestigationalCositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.
Rocaglamide
go.drugbank.com/drugs/DB15495Experimental[didesmethylrocaglamide]) are currently being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas, and carcinomas, as well as adjuvant therapy in the treatment of … [A186796] Reports of _Aglaia_ anti-tumor activity date back as far as 1973, and rocaglamide-A was first isolated in 1982 from the species _A. elliptifolia_.